These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24909083)

  • 21. Expression and characterization of catalytic domain of Plasmodium falciparum subtilisin-like protease 3.
    Alam A; Bhatnagar RK; Chauhan VS
    Mol Biochem Parasitol; 2012 May; 183(1):84-9. PubMed ID: 22285468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors.
    Mishra N; Agrahari AK; Bose P; Singh SK; Singh AS; Tiwari VK
    Sci Rep; 2020 Feb; 10(1):3586. PubMed ID: 32108142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
    Chaudhary M; Singh V; Anvikar AR; Sahi S
    Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteolytic activity of Plasmodium falciparum subtilisin-like protease 3 on parasite profilin, a multifunctional protein.
    Alam A; Bhatnagar RK; Relan U; Mukherjee P; Chauhan VS
    Mol Biochem Parasitol; 2013 Oct; 191(2):58-62. PubMed ID: 24080030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of piperazine-based hydroxamic acid inhibitors against falcilysin, an essential malarial protease.
    Chance JP; Fejzic H; Hernandez O; Istvan ES; Andaya A; Maslov N; Aispuro R; Crisanto T; Nguyen H; Vidal B; Serrano W; Kuwahara B; Pugne Andanado C; Goldberg DE; Mallari JP
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1846-1848. PubMed ID: 29691139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion.
    Nasamu AS; Glushakova S; Russo I; Vaupel B; Oksman A; Kim AS; Fremont DH; Tolia N; Beck JR; Meyers MJ; Niles JC; Zimmerberg J; Goldberg DE
    Science; 2017 Oct; 358(6362):518-522. PubMed ID: 29074774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.
    Pan H; Yang K; Zhang J; Xu Y; Jiang Y; Yuan Y; Zhang X; Xu W
    J Enzyme Inhib Med Chem; 2013 Aug; 28(4):717-26. PubMed ID: 22545941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
    Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of first-in-class plasmodium OTU inhibitors with potent anti-malarial activity.
    Siyah P; Akgol S; Durdagi S; Kocabas F
    Biochem J; 2021 Sep; 478(18):3445-3466. PubMed ID: 34486667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ca(2+) -mediated exocytosis of subtilisin-like protease 1: a key step in egress of Plasmodium falciparum merozoites.
    Agarwal S; Singh MK; Garg S; Chitnis CE; Singh S
    Cell Microbiol; 2013 Jun; 15(6):910-21. PubMed ID: 23217145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
    Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
    Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global identification of multiple substrates for Plasmodium falciparum SUB1, an essential malarial processing protease.
    Silmon de Monerri NC; Flynn HR; Campos MG; Hackett F; Koussis K; Withers-Martinez C; Skehel JM; Blackman MJ
    Infect Immun; 2011 Mar; 79(3):1086-97. PubMed ID: 21220481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18.
    Paiardini A; Bamert RS; Kannan-Sivaraman K; Drinkwater N; Mistry SN; Scammells PJ; McGowan S
    PLoS One; 2015; 10(2):e0115859. PubMed ID: 25700165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designed Parasite-Selective Rhomboid Inhibitors Block Invasion and Clear Blood-Stage Malaria.
    Gandhi S; Baker RP; Cho S; Stanchev S; Strisovsky K; Urban S
    Cell Chem Biol; 2020 Nov; 27(11):1410-1424.e6. PubMed ID: 32888502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Plasmodium falciparum protease inhibitors in the past decade (2002-2012).
    Pérez B; Teixeira C; Gomes JR; Gomes P
    Curr Med Chem; 2013; 20(25):3049-68. PubMed ID: 23514416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.
    Hodder AN; Sleebs BE; Czabotar PE; Gazdik M; Xu Y; O'Neill MT; Lopaticki S; Nebl T; Triglia T; Smith BJ; Lowes K; Boddey JA; Cowman AF
    Nat Struct Mol Biol; 2015 Aug; 22(8):590-6. PubMed ID: 26214367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achiral, cheap, and potent inhibitors of Plasmepsins I, II, and IV.
    Boss C; Corminboeuf O; Grisostomi C; Meyer S; Jones AF; Prade L; Binkert C; Fischli W; Weller T; Bur D
    ChemMedChem; 2006 Dec; 1(12):1341-5. PubMed ID: 17091526
    [No Abstract]   [Full Text] [Related]  

  • 39. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
    Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
    Molecules; 2018 May; 23(6):. PubMed ID: 29794978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autocatalytic activation of a malarial egress protease is druggable and requires a protein cofactor.
    Tan MSY; Koussis K; Withers-Martinez C; Howell SA; Thomas JA; Hackett F; Knuepfer E; Shen M; Hall MD; Snijders AP; Blackman MJ
    EMBO J; 2021 Jun; 40(11):e107226. PubMed ID: 33932049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.